Latest Breaking News On - Junshi biosciences contact informationir team - Page 1 : vimarsana.com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing com

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer By Investing com
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoPabout toripalimabJunshi bioscienceszhiJunshi biosciencesSingapore health sciences authorityUniversity cancer hospitalJunshi biosciences contact informationir teamEuropean medicines agencyAustralia therapeutic goods administrationInternational metastatic renal cell carcinoma database consortiumPr teamNational medical products administrationShanghai junshi biosciences co ltdNational reimbursement drug listProfessor jun

Junshi Biosciences Announces Toripalimab s NDA Accepted by the Singapore Health Sciences Authority

Junshi Biosciences Announces Toripalimab s NDA Accepted by the Singapore Health Sciences Authority
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoJunshi bioscienceszhi liJunshi biosciencesDrug administrationJunshi biosciences contact informationir teamOncology centerJournal of the american medical associationRegulatory agencyEuropean unionWorld health organizationPr teamAustralia therapeutic goods administrationAmerican society of clinical oncologyShanghai junshi biosciences co ltd

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJudy steckerJunshi biosciencesDenny lanfearRuihua xuZhi liCoherus biosciencescoherusJodi sieversEndocrinopathiesadrenal insufficiencyJunshi bioscienceSolutions coherusShanghai junshi biosciences co ltdHospital cancer centerDrug administrationExchange commissionVp corporate communications

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ying chengSan franciscoUnited statesJunshi biosciencesJunshi bioscienceJunshi bioscienceszhi liOncology congressShanghai junshi biosciences co ltdNational medical products administrationEuropean society of oncologistsShanghai jiao tong university school of medicineJunshi biosciences contact informationir teamGlobal researchPr teamEuropean societyImmuno oncology congress

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesJunshi bioscienceszhi liJunshi bioscienceJunshi biosciencesUniversity cancer hospitalRegulatory agencyRadiographic review committeePr teamJunshi biosciences contact informationir teamNational reimbursement drug listDrug administrationShanghai jiao tong university school of medicineNational medical products administrationEuropean medicines agency